Drug Profile
BMS 986278
Alternative Names: BMS-986278Latest Information Update: 06 Feb 2024
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antifibrotics; Carbamates; Cyclohexanecarboxylic acids; Pyridines; Small molecules; Triazoles
- Mechanism of Action Lysophosphatidic acid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Idiopathic pulmonary fibrosis; Pulmonary fibrosis
Most Recent Events
- 11 Dec 2023 Bristol-Myers Squibb completes a phase I pharmacokinetic trial (In volunteers) in Canada (PO) (NCT05985590)
- 25 Oct 2023 Phase-III clinical trials in Pulmonary fibrosis in United Kingdom, Turkey, Spain, Portugal, Poland, Peru, Netherlands, Mexico, Italy, Israel, Ireland, India, Greece, Germany, France, Denmark, Colombia, China, Chile, Brazil, Belgium, Australia, USA (PO) (NCT06025578)
- 24 Oct 2023 BMS 986278 receives Breakthrough Therapy status for Idiopathic pulmonary fibrosis in USA